Celltrion's STEQEYMA® (ustekinumab-stba), now added to the Costco Member Prescription Program
Celltrion, Inc., today announced that STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab) has been added to ...
Medical Device Network on MSN20h
Enable Injections’ syringe transfer system gains CE mark approval
Enable Injections’ enFuse Syringe Transfer System has secured CE mark approval under the European Union Medical Device ...
The Daily Item1d
Enhanced penalty for fatal drug deaths, ban on safe injection sites get initial OK in Pa. Senate
The Pennsylvania Senate took steps Tuesday to enact separate legislation that would ban safe injection sites for drug use and ...
Providence’s safe injection site sees hundreds in first two months
Program leaders say the country’s first state-sanctioned overdose prevention center, operated by Project Weber/RENEW, has ...
Tharimmune Announces Positive Results for Novel Oral Monoclonal Antibody TH023 Targeting Tumor Necrosis Factor-alpha
Tharimmune, Inc. (Nasdaq:THAR) (”Tharimmune” or the “Company”), a clinical-stage biotechnology company focused on immunology and inflammation, today announced positive preclinical results for its ...
News244d
A jab that could protect against HIV for a year at a time
A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV ...
The American Journal of Managed Care5d
FDA Approves Guselkumab for Adult Patients With Crohn Disease
The FDA has approved guselkumab (Tremfya) as the first IL-23 inhibitor offering both subcutaneous and intravenous induction ...
AllAfrica on MSN5d
A Jab That Could Protect Against HIV for a Year At a Time, and Other Highlights From Major Conference
A single shot of a new formulation of the antiretroviral drug lenacapavir could potentially provide protection against HIV infection for as long as a year. Spotlight reports on this and some of the ...
Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers
Weekly subcutaneous administration of sabirnetug was well-tolerated in the Phase 1 study Systemic exposure following subcutaneous administration ...